Zalfermin

泽拉夫明

Report date: 2024/08/01 16:14:43

Base Information

Drug NameZalfermin
Drug Alias NameNNC-0194-0499NN-9499NNC-01940499NNC0194-0499NN9499 +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionFibroblast growth factor receptors agonists
TargetsFibroblast growth factor receptors
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 1Nutritional and Metabolic Diseases +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[27] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesNovo Nordisk A/SNovo Nordisk (China)Pharmaceuticals Co LtdNovo Nordisk Pharmaceuticals
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 1Hepatitis, AlcoholicHepatic Insufficiency +[4] 
Inactive IndicationsObesityNutritional and Metabolic Diseases

Other Information

ATC CodeN/A
Related LinksN/A